From referral to infusion: Accelerating the CAR-T process

There are many frustrating aspects to a cancer diagnosis.
Perhaps the most challenging is the waiting required for everything from test results to diagnosis confirmation to treatment initiation.
Patients eligible for chimeric antigen receptor T-cell therapy typically have high-risk or advanced disease that requires timely treatment to achieve maximum benefits, according to Jason Westin, MD, MS, FACP, director of lymphoma clinical research and section chief for aggressive lymphoma at The University of Texas MD Anderson Cancer Center and chair of the Government Relations Committee for ASCO.

There are many frustrating aspects to a cancer diagnosis.
Perhaps the most challenging is the waiting required for everything from test results to diagnosis confirmation to treatment initiation.
Patients eligible for chimeric antigen receptor T-cell therapy typically have high-risk or advanced disease that requires timely treatment to achieve maximum benefits, according to Jason Westin, MD, MS, FACP, director of lymphoma clinical research and section chief for aggressive lymphoma at The University of Texas MD Anderson Cancer Center and chair of the Government Relations Committee for ASCO.